As 2025 comes to a close, BioNTX reflects on a year
of innovation, growth, and achievement across North Texas’ life science ecosystem,
highlighted by the accomplishments of the 2025 Rising Stars. These eight high-potential
companies have demonstrated exceptional leadership and scientific innovation, earning
recognition at BioNTX’s flagship iC³® Life Science & Healthcare Innovation Summit,
culminating in the Rising Star Investor Dinner.
The Rising Stars program is a cornerstone BioNTX platform designed to elevate
emerging companies by providing visibility, credibility, and direct access to investors,
industry leaders, and strategic partners. More than an award, the program serves as a
curated pathway that connects standout innovators to the region’s broader life science
ecosystem.
The 2025 Rising Stars were first recognized on the main stage at iC³®, where they were
introduced to an audience of investors, corporate leaders, researchers, and
policymakers. That recognition was followed the Rising Star Investor Dinner—an
intimate gathering bringing together current and past Rising Stars, and investors, for
meaningful conversation, networking, and another opportunity to present their
company.
“The Rising Stars program exemplifies the energy, creativity, and ambition that make
our region a national leader in life sciences,” said Kathleen Otto-Rosenblum, CEO of
BioNTX. “By connecting these innovators with investors and partners, we are not just
recognizing their success—we are accelerating it. This platform is a catalyst for growth,
collaboration, and real-world impact.”
A special thank-you goes to the evening’s fireside chat guests—Kristen Doyle, CEO of
Cancer Prevention & Research Institute of Texas (CPRIT), and Eric Danielson, Managing
Director and Head of Real Estate Development at NexPoint. Their insights and
perspectives set a powerful tone for the event, underscoring the connectivity, shared
purpose, and momentum that define North Texas’ life science ecosystem.
BioNTX also recognizes the generous support of its sponsors—Baker Tilly, Cowtown
Angels, the Davis/Yost Group at Morgan Stanley, NexPoint, TechFW, and the Texas
Research Quarter—whose commitment ensures that rising innovators across the region
continue to be seen, supported, and elevated.
2
2025 BioNTX Rising Star Recipients
- EidoBio – advancing precision medicine tools to unlock new possibilities in
diagnostics and treatment for women’s health - Metaclipse Therapeutics – pioneering immune-based therapies for cancer and
infectious diseases - Moleculera Biosciences – leading the way in neuro-immune diagnostics to
improve brain health and patient outcomes - ParaNano Wound Care – developing next-generation antimicrobial
nanotechnologies to fight infection and accelerate healing - Stingray Therapeutics – driving innovation in oncology with novel approaches to
modulating the immune system - StitchLock – transforming surgical care with breakthrough wound closure
technology - SyntaxisBio – engineering advanced biologics and therapeutics with scalable,
real-world applications - Telos Biotech – redefining gene and cell therapy platforms with bold new
approaches to delivery and safety
Through Rising Stars, BioNTX emphasizes investor exposure, ecosystem integration,
and sustained engagement, ensuring companies are celebrated, supported, and
positioned for growth. Participants gain access to curated introductions, high-profile
platforms, and relationship-building opportunities that extend well beyond a single
event.
BioNTX congratulates the 2025 Rising Stars and looks forward to supporting their
continued growth and success in the year ahead.
About BioNTX
BioNTX is the bioscience and healthcare innovation trade organization serving the
North Texas region. The organization fosters innovation and community through
collaborative networking events, educational programming, professional development,
market visibility, a purchasing consortium, and by being the voice for the North Texas
biosciences and healthcare innovation community.
